Group 1 - The report highlights that the new consumption sector performed well, with service consumption policies expected to continue catalyzing growth in 2026 [2][27] - In 2025, the overall performance of the optional consumption sector was weak, but sub-sectors like new consumption showed significant gains, particularly in the first half of the year [16][21] - The retail sales of consumer goods grew moderately, with service retail growth outpacing that of goods retail, indicating a shift towards service consumption [21][27] Group 2 - The tourism sector is expected to benefit from extended holiday periods and improved vacation policies, with companies like Trip.com and Tongcheng Travel being key focuses [3] - The hotel market is showing signs of recovery, with a narrowing decline in RevPAR and increasing leisure demand, highlighting companies like Jin Jiang Hotels and Huazhu Group [3] - The duty-free sector is experiencing a boost from new policies, particularly in Hainan, with a focus on high-end consumption recovery [3] Group 3 - The cosmetics industry saw a slight growth of 6.18% in 2025, with domestic brands continuing to gain market share [4][30] - The medical beauty market is projected to reach approximately 366.6 billion in 2025, with a K-shaped consumption differentiation emerging [4][30] - Innovations in core ingredients and the integration of biotechnology are driving brand growth in the cosmetics sector [4][36] Group 4 - The IP derivative market is expanding due to a flourishing supply of IP and commercial operations, with domestic policies expected to further mature the industry ecosystem [5] - Key players in the IP space include Shanghai Film, Light Media, and Pop Mart, with a focus on both domestic and international market expansion [5] Group 5 - The gold and jewelry sector saw a cumulative growth of 12.78% in retail sales from January to December, with a focus on brand premium capabilities and international expansion [6][9] - The rise of "self-wearing" scenarios is driving gold jewelry sales, with brands like Chao Hong Ji and Lao Pu Gold being highlighted for their international strategies [9]

Medical Aesthetics - Jiangsu Chuangjian Medical Technology Co., Ltd. received approval for its cross-linked recombinant collagen implant, marking a significant development in the medical aesthetics market [2][17] - The product is designed for facial dermal tissue filling to correct moderate to severe dynamic wrinkles, making it the fifth recombinant collagen implant approved in China and the first cross-linked version [17] - The recombinant collagen industry is shifting from "single type" to "diverse structure," with companies accelerating competition towards full-scenario applications [18] Cosmetics - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, officially listed on the Hong Kong Stock Exchange, becoming the first high-end domestic skincare brand to go public [3][19] - The company has established a comprehensive supply chain system and a unique OMO (Online-Merge-Offline) channel model, which integrates online and offline sales to enhance customer engagement and drive growth [23][35] - Lin Qingxuan's flagship product, the camellia oil essence, has achieved a leading repurchase rate of 33.5% in the industry, indicating strong customer loyalty [27][46] Investment Recommendations - The company recommends focusing on differentiated upstream medical aesthetics product manufacturers and chain medical institutions, highlighting the potential of Meili Tianyuan Medical Health [4][48] - In the cosmetics sector, the emphasis is on domestic brands that innovate in emotional value and safe ingredients, with key recommendations including Lin Qingxuan and other brands that leverage both online and offline channels [4][47] Market Performance - In December, the beauty and personal care index fell by 1.70%, underperforming the broader market, while the medical aesthetics sector saw notable gains from companies like Meili Tianyuan Medical Health and Jinbo Biological [5][10] - For the full year of 2025, the medical aesthetics sector showed mixed performance, with companies like Sihuan Pharmaceutical and Yonghe Medical leading in growth [10] Financial Highlights - Lin Qingxuan reported a total revenue of 1.05 billion yuan in the first half of 2025, reflecting a year-on-year growth of 98.3%, primarily driven by its camellia oil essence [23][41] - The company's gross margin remains high at 82.4%, with specific product categories like essence oil achieving even higher margins [23][41]

Investment Rating - The industry investment rating is "Positive" (首次) [1] Core Insights - The beauty and personal care industry is experiencing a mixed performance, with the beauty care index declining by 1.70% in December 2025, ranking 24th among all primary industries [15] - The medical beauty sector is seeing innovation with the approval of new products, such as the cross-linked recombinant collagen implant by Jiangsu Chuangjian Medical Technology Co., which is expected to inject new momentum into the market [7][34] - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone for domestic high-end skincare brands [8][39] Summary by Sections Market Review - In December, the beauty care index reported a decline of 1.70%, underperforming the broader market, which saw the Shanghai Composite Index increase by 2.06% [15] - For the entire year of 2025, the beauty care index showed a cumulative increase of 0.39%, again lagging behind the Shanghai Composite Index's 18.41% growth [15] Medical Beauty - Jiangsu Chuangjian Medical's cross-linked recombinant collagen implant has been approved, making it the fifth such product in China and the first cross-linked version [34] - The industry is shifting from single product competition to a full-chain layout, with companies like Jinjian Biological and Junzi Biological also making significant advancements in the recombinant collagen space [34][36] Cosmetics - Lin Qingxuan has established itself as a leader in the high-end domestic skincare market, achieving the highest retail sales among domestic brands in 2024 [39] - The company has built a comprehensive supply chain and employs an OMO (Online-Merge-Offline) model to enhance customer engagement and sales [39][49] - Lin Qingxuan's core product, the camellia oil essence, has a high repurchase rate of 33.5%, indicating strong customer loyalty [51] Investment Recommendations - The report recommends focusing on differentiated upstream medical beauty product manufacturers and chain medical beauty institutions, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][53] - In cosmetics, the report suggests investing in brands that innovate in emotional value and safe ingredients, with a focus on domestic brands like Maogeping and Lin Qingxuan [54]

Group 1 - The core viewpoint of the article highlights the positive performance of the healthcare sector, particularly in the fields of collagen and skincare products, with significant growth opportunities identified [1] - The Medical Industry ETF (159877.SZ) increased by 4.05%, and Lepu Medical surged by 19.99%, indicating strong market interest and investor confidence in the sector [1] - Jianghai Securities emphasizes the multi-dimensional investment logic in the healthcare industry, particularly in the collagen sector, where new entrants like Chuangjian Medical are gaining traction with their cross-linked collagen implants [1] Group 2 - The approval of cross-linked collagen products by Chuangjian Medical positions it as a strong competitor in the market, following the successes of Jinbo Biology and Juzhi Biology [1] - The "oil-based skincare" segment is projected to see sales exceeding 9.5 billion yuan from March 2024 to February 2025, reflecting a 36% growth, driven by advancements in domestic brands [1] - Continuous improvements in ingredients, technology, and formulations are enhancing industry standards, further propelling growth in the healthcare sector [1]

Investment Rating - Industry rating: "Accumulate" (maintained) [7] Core Insights - The approval of the cross-linked recombinant collagen implant by Chuangjian Medical on December 23, 2025, marks a significant addition to the recombinant collagen industry, which is expected to expand further [7] - Lin Qingxuan has passed the Hong Kong Stock Exchange listing hearing, potentially becoming the first high-end domestic skincare stock in Hong Kong [7] - The "oil-based skincare" brand Afu released the industry's first technical standard for functional skincare products on December 8, 2025, supporting the standardized development of the "oil-based skincare" sector [7] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -21.5% compared to the CSI 300 index, with absolute returns of -4.52% [3] Key Events - Chuangjian Medical's recombinant collagen implant is composed of cross-linked recombinant collagen hydrogel and is approved for facial dermal filling to correct moderate to severe dynamic wrinkles [7] - Lin Qingxuan's core product, camellia oil essence, has seen its revenue share increase from 31.5% in 2022 to an expected 45.5% in the first half of 2025, maintaining its position as the top-selling facial essence oil in China for 11 consecutive years [7] Investment Recommendations - The successful approval of Chuangjian Medical's product is expected to enhance industry growth, with a recommendation to monitor the product's market performance post-launch [7] - The sales of essence oils across major online platforms are projected to exceed 9.5 billion yuan from March 2024 to February 2025, with facial essence oils experiencing a 36% growth, indicating a strong market demand [7]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index declining by 1.1% from December 19 to December 26, 2025, which is weaker than the market performance [4][5]. - Lin Qingxuan is set to lead the high-end domestic essence oil sector with its upcoming IPO on December 30, 2025, planning to issue 13.9665 million H shares. The company has shown significant growth, with revenue projected to increase from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a compound annual growth rate (CAGR) of 32.7% [4][10]. - The report highlights the strong performance of Yiwang Yichuang (300792SZ) in the e-commerce agency sector, leveraging AI to enhance operational efficiency and revenue potential [11][12]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with specific indices showing declines: the Shenwan Cosmetics Index fell by 1.3%, and the Shenwan Personal Care Index decreased by 1.0% [4][5]. Key Company Developments - Lin Qingxuan's IPO is anticipated to bolster its market position, with a focus on high-end skincare products. The company has achieved a market share of 1.4% in the high-end skincare segment and ranks 10th in the anti-wrinkle product market with a 2.2% share [10]. - Yiwang Yichuang's business model is robust, with a comprehensive coverage of consumer goods categories and deep collaboration with Alibaba, positioning it well for future growth [11][12]. Market Trends - The report notes a recovery in the e-commerce agency sector, driven by increased demand for brand representation on platforms like Alibaba, with a notable rebound in traffic [12][13]. - The overall retail sales of cosmetics in China showed a growth of 4.8% year-on-year for the first 11 months of 2025, with November alone seeing a 6.1% increase, aided by promotional events [18][20]. Regulatory and Product Innovations - Jiangsu Chuangjian Medical Technology's collagen implant product received approval from NMPA, indicating ongoing innovation in the medical beauty sector [22]. - The report also mentions the investment by L'Oréal in a Chinese pharmaceutical company, marking a significant move into the skin health sector [25].

Investment Rating - The report indicates a cautious outlook for the cosmetics and medical beauty sector, with the beauty care index declining by 1.1% from December 19 to December 26, 2025, underperforming the market [3][4]. Core Insights - Lin Qingxuan is set to lead the high-end domestic essence oil market with its upcoming IPO on December 30, 2025, aiming to issue 13.9665 million H shares. The brand has established itself as a benchmark in high-end domestic skincare, with a market share of 1.4% in 2024, ranking 13th among high-end skincare brands [3][8]. - The company has shown impressive growth, with revenue increasing from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a compound annual growth rate (CAGR) of 32.7%. The net profit margin for the first half of 2025 reached 17.3%, with net profit doubling to 182 million yuan year-on-year [3][8]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has underperformed the market, with the cosmetics index down 1.3%, lagging behind the Shenwan A index by 4.2 percentage points [3][4]. - The top-performing stocks in the sector included Yanjiang Co. (+10.9%), Mingchen Health (+9.2%), and Hongmian Co. (+8.6%), while the worst performers were Nobon Co. (-4.0%), Mengyue Care (-3.4%), and Shangmei Co. (-3.1%) [4]. Key Company Updates - Yiwang Yichuang (300792SZ) is highlighted for its robust operational foundation in e-commerce agency services, leveraging AI to enhance performance. The company has seen a turnaround in net profit growth, with a 4% year-on-year increase in the first three quarters of 2025 [9][10]. - The approval of Jiangsu Chuangjian Medical's "cross-linked recombinant collagen implant" on December 24, 2025, marks a significant advancement in the medical beauty sector, targeting facial dermal filling [19][21]. Market Trends - The retail sales of cosmetics in China for the first eleven months of 2025 reached 428.5 billion yuan, with a year-on-year growth of 4.8%. The sales in November alone grew by 6.1%, driven by promotional events [16][20]. - The report notes a shift in market dynamics, with domestic brands gaining market share against international competitors. In 2024, the domestic skincare market is projected to reach 271.2 billion yuan, despite a decline of 3.7% year-on-year [24][26].

Core Viewpoint - The medical aesthetics industry is entering a "cooling period" by 2025, with increasing competition leading to performance declines for upstream companies, making it challenging for leading manufacturers to maintain high growth rates. Price wars are becoming inevitable as the number of competitors rises, and conflicts over product pricing and agency rights are escalating among companies [1][2][4]. Industry Overview - The medical aesthetics market is approaching saturation, with many listed companies experiencing significant declines in performance. For instance, Huaxi Biological reported a revenue drop of 18.36% and a net profit decline of 30.29% for the first three quarters of the year. Similarly, Aimeike experienced a revenue decrease of 21.49% and a net profit drop of 31.05% [2][3]. - Despite the current challenges, industry experts remain optimistic about the future growth of the medical aesthetics market, projecting a double-digit growth rate driven by consumer preferences and increasing demand for aesthetic procedures [3][4]. Competitive Landscape - The approval of various hyaluronic acid and collagen products has intensified competition, leading to a "price war" among manufacturers. The market for "童颜针" (AestheFill) has seen a significant increase in competition, with multiple products now available, creating a scenario referred to as "九子夺嫡" (Nine Princes Competing for the Throne) [4][5][6]. - The pricing strategies of downstream institutions are causing conflicts with upstream manufacturers, as some institutions adopt low-price strategies that disrupt traditional pricing systems [4][5]. Mergers and Acquisitions - The industry is witnessing a wave of mergers and acquisitions as companies seek to acquire technology, brands, or channel resources. Notable transactions include Aimeike's acquisition of a majority stake in Korean REGEN and Bausch Health's acquisition of Wuhan Zhibo Zhenmei Technology [6][7]. - The trend of consolidation is expected to continue, with both upstream and downstream companies engaging in strategic acquisitions to enhance their market positions and operational efficiencies [7].